MedTrace Logo

Chemoradiotherapy for Patients With Oligometastatic Colorectal Cancer

NCT01759238 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2022-07-01

No results posted yet for this study

Summary

This study tries to evaluate the role of chemoradiation with capecitabine and bevacizumab in oligometastatic patients neither being progressive nor resectable after chemotherapy.

Conditions

Interventions

DRUG

Capecitabine

825mg/m2 per os bid

DRUG

Bevacizumab

7.5 mg/kg

RADIATION

Radiotherapy

(conventional or intensity-modulated and image-guided radiotherapy)

Sponsors & Collaborators

  • Universitätsklinikum Hamburg-Eppendorf

    lead OTHER

Principal Investigators

  • Cordula Petersen, Prof. · Universitätsklinikum Hamburg-Eppendorf

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-05-31
Primary Completion
2014-10-31
Completion
2014-10-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01759238 on ClinicalTrials.gov